Supernus Pharmaceuticals Inc (SUPN)
29.98
+0.27
(+0.91%)
USD |
NASDAQ |
Apr 23, 16:00
29.95
-0.03
(-0.10%)
After-Hours: 20:00
Supernus Pharmaceuticals Enterprise Value: 1.386B for April 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 23, 2024 | 1.386B |
| April 22, 2024 | 1.371B |
| April 19, 2024 | 1.354B |
| April 18, 2024 | 1.325B |
| April 17, 2024 | 1.332B |
| April 16, 2024 | 1.356B |
| April 15, 2024 | 1.387B |
| April 12, 2024 | 1.400B |
| April 11, 2024 | 1.497B |
| April 10, 2024 | 1.488B |
| April 09, 2024 | 1.482B |
| April 08, 2024 | 1.465B |
| April 05, 2024 | 1.581B |
| April 04, 2024 | 1.565B |
| April 03, 2024 | 1.598B |
| April 02, 2024 | 1.561B |
| April 01, 2024 | 1.580B |
| March 28, 2024 | 1.612B |
| March 27, 2024 | 1.592B |
| March 26, 2024 | 1.523B |
| March 25, 2024 | 1.538B |
| March 22, 2024 | 1.635B |
| March 21, 2024 | 1.670B |
| March 20, 2024 | 1.654B |
| March 19, 2024 | 1.669B |
| Date | Value |
|---|---|
| March 18, 2024 | 1.617B |
| March 15, 2024 | 1.550B |
| March 14, 2024 | 1.572B |
| March 13, 2024 | 1.642B |
| March 12, 2024 | 1.547B |
| March 11, 2024 | 1.520B |
| March 08, 2024 | 1.446B |
| March 07, 2024 | 1.432B |
| March 06, 2024 | 1.448B |
| March 05, 2024 | 1.406B |
| March 04, 2024 | 1.422B |
| March 01, 2024 | 1.442B |
| February 29, 2024 | 1.371B |
| February 28, 2024 | 1.446B |
| February 27, 2024 | 1.425B |
| February 26, 2024 | 1.360B |
| February 23, 2024 | 1.336B |
| February 22, 2024 | 1.274B |
| February 21, 2024 | 1.285B |
| February 20, 2024 | 1.280B |
| February 16, 2024 | 1.300B |
| February 15, 2024 | 1.313B |
| February 14, 2024 | 1.253B |
| February 13, 2024 | 1.229B |
| February 12, 2024 | 1.297B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
757.21M
Minimum
Mar 18 2020
2.362B
Maximum
Apr 21 2023
1.519B
Average
1.519B
Median
Sep 27 2019
Enterprise Value Benchmarks
| Dynavax Technologies Corp | 1.016B |
| Ligand Pharmaceuticals Inc | 1.067B |
| Pacira BioSciences Inc | 1.491B |
| Esperion Therapeutics Inc | 566.11M |
| Collegium Pharmaceutical Inc | 1.505B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.175M |
| Revenue (Quarterly) | 164.31M |
| Total Expenses (Quarterly) | 145.32M |
| EPS Diluted (Quarterly) | 0.0174 |
| Gross Profit Margin (Quarterly) | 88.06% |
| Profit Margin (Quarterly) | 0.72% |
| Earnings Yield | -0.01% |
| Operating Earnings Yield | 0.79% |
| Normalized Earnings Yield | 0.8903 |